Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Bamadutide in Healthy Men and T2DM Patients
NCT02411825Phase 1Completed
- Sponsor
- Sanofi
- Start
- Mar 2015
- Primary completion
- Jan 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bamadutide in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Sanofi. Primary endpoint: Number of adverse events at 35 days. Started Mar 2015; status: completed.
02
Drugs
bamadutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT02411825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02411825.